Table 1.
Baseline sociodemographic, clinical, and healthcare use characteristics.
| Characteristic | Total (n = 201) | Female patients (n = 62, 30.8%) | Male patients (n = 139, 69.2%) | p value | Missing N |
|---|---|---|---|---|---|
| Age at onset of psychosis: mean (SD) | 26.3 (8.4) | 28.0 (8.4) | 25.5 (8.2) | 0.048 | 2 |
| Age: mean (SD) | 27.5 (8.3) | 29.0 (8.4) | 26.8 (8.2) | 0.082 | 1 |
| Years of education: mean (SD) | 14.2 (2.3) | 15.2 (1.5) | 13.8 (2.4) | < 0.001 | 3 |
| PANSS score: mean (SD) | 1 | ||||
| Positive scale | 9.1 (2.6) | 8.5 (2.3) | 9.4 (2.8) | 0.035 | |
| Negative scale | 11.8 (4.2) | 11.5 (4.3) | 11.9 (4.2) | 0.529 | |
| General scale | 22.8 (5.2) | 22.6 (4.9) | 22.9 (5.3) | 0.719 | |
| Total | 43.7 (9.5) | 42.6 (8.9) | 44.2 (9.8) | 0.290 | |
| WHO-DAS 2.0 score: mean (SD) | 17.8 (15.0) | 19.1 (16.9) | 17.2 (14.1) | 0.400 | 2 |
| GAF: mean (SD) | 66.1 (12.1) | 68.0 (12.3) | 65.3 (12.0) | 0.158 | 4 |
| Antipsychotic medication: n (%) | 0 | ||||
| Aripiprazole | 61 (30.3%) | 20 (32.3%) | 41 (29.5%) | 0.446 | |
| Olanzapine | 69 (34.3%) | 24 (38.7%) | 45 (32.4%) | ||
| Other types | 71 (35.3%) | 18 (29.0%) | 53 (38.1%) | ||
| Dose of antipsychotic medication (Olanzapine equivalent): mean (SD) | 9.5 (6.0) | 9.1 (6.6) | 9.7 (5.7) | 0.495 | 1 |
| Participants who tapered antipsychotic medication between baseline and 12 months follow-up: n (%) | 145 (82.9%) | 42 (85.6) | 94 (81.7) | 0.664 | 37 |
| Dose reduction (%) of antipsychotic medication between baseline and 12 months: mean (SD) | 64.1% (56.1) | 71.9 (44.3) | 60.7 (60.4) | 0.231 | 28 |
Abbreviations: PANSS, Positive and Negative Syndrome Scale; WHO-DAS, World Health Organisation Disability Assessment Schedule; GAF, Global Assessment of Functioning.